News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

KEY COMPOUND PATENT FOR PLEDOX® AND ALADOTE® SET TO GAIN US APPROVAL

September 22, 2015

PledPharma AB
Company Announcement

KEY COMPOUND PATENT FOR PLEDOX® AND ALADOTE® SET TO GAIN US APPROVAL

PledPharma AB (publ) today reports that the United States Patent and Trademark
Office (USPTO) has announced a "Notice of Allowance" for PledPharma's patent
for the active ingredient of the drug candidates PledOx® and Aladote®. A Notice
of Allowance means that the USPTO intends to grant the application. 

Stockholm, 2015-09-22 08:30 CEST (GLOBE NEWSWIRE) -- 

The announcement from the USPTO refers to patent application 14/369, 153,
entitled "Calmangafodipir, a New Chemical Entity, and Other Mixed Metal
Complexes, Methods of Preparation, Compositions, and Methods of Treatment". The
patent term extends to December 2032 

"The compound patent for PledOx® and Aladote® offers strong intellectual
property protection in the US market and is therefore of great value to us, not
least in negotiations with potential licensees for our most advanced project
PledOx®. The patent for which we received a Notice of Allowance is the
centerpiece of our broad patent portfolio, "said PledPharma CEO Jacques
Näsström. 

PledOx® has been developed to provide patients with colorectal cancer
protection against the chemotherapy induced nerve damage that often occurs in
conjunction with cancer treatment. These kind of side effects often lead to the
prescribed chemotherapy dose having to be reduced, or, in the worst case, to
discontinuation of the treatment. Aladote® is a drug candidate with the
potential to prevent the acute liver failure associated with overdoses of 
acetaminophen - the most common method of suicide attempts among young people
aged 10-19 years. 



FOR FURTHER INFORMATION CONTACT:

Jacques Näsström, CEO PledPharma AB
cell: +46 73 713 09 79
e-mail: jacques.nasstrom@pledpharma.se



PLEDPHARMA IN BRIEF

PledPharma develops new drugs that protect the body against oxidative stress –
a condition that can be caused by chemotherapy treatment and acetaminophen
(paracetamol) poisoning. The company's most advanced project PledOx® reduces
the nerve damage associated with chemotherapy. The drug candidate Aladote® is
being developed to reduce the risk of acute liver failure associated with
acetaminophen poisoning. The project PP-099 seeks to limit the damage that
occurs to the heart muscle during myocardial infarction. PledPharma’s most
advanced project with PledOx® has completed Phase II trial. PledPharma (STO:
PLED) is listed on Nasdaq First North. Erik Penser Bankaktiebolag is the
company’s Certified Adviser (tel +46 8 463 80 00). 
For more information, see www.pledpharma.se



PledPharma AB discloses the information provided herein pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com